Drug intelligence / Profile preview

Ganoderma sinense polysaccharide

Development stage: Unknown
Administration: Oral

Overview

Ganoderma sinense polysaccharide (GSP) is a glycan-based adjunctive therapeutic drug approved in China. It is utilized in cancer treatment to mitigate leukopenia and hematopoietic injury induced by concurrent chemotherapy and radiation therapy. Preclinical and basic research indicate that GSP exhibits antitumor, antioxidant, anticytopenia, and unique mushroom-poison detoxification properties. Its primary mechanism of action involves immunomodulation, with β-glucan identified as one of its key immunostimulating components.

Other names: GSP

Beyond the preview

Go deeper on Ganoderma sinense polysaccharide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ganoderma sinense polysaccharide.

Explore the full profile